BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/25/2023 2:17:08 PM | Browse: 112 | Download: 238
 |
Received |
|
2023-03-12 18:51 |
|
Peer-Review Started |
|
2023-03-12 18:54 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-03-23 20:59 |
|
Revised |
|
2023-04-01 23:27 |
|
Second Decision |
|
2023-04-17 03:08 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-04-18 02:24 |
|
Articles in Press |
|
2023-04-18 02:24 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-06-16 08:16 |
|
Publish the Manuscript Online |
|
2023-06-25 14:17 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Treatment of liver fibrosis: Past, current, and future
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chun-Ye Zhang, Shuai Liu and Ming Yang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ming Yang, DVM, PhD, Postdoctoral Fellow, Department of Surgery, University of Missouri, Room 2203, NexGen Precision Building, 1030 Hitt Street, Columbia, Missouri 65211, United States. yangmin@health.missouri.edu |
| Key Words |
Liver fibrosis; Molecular mechanism; Therapeutic targets; Treatments; Clinical trials |
| Core Tip |
Liver fibrosis accompanies the progression of chronic liver diseases independent of their etiologies. The initiation and progression of liver fibrosis are mainly driven by liver inflammation, cell death, and metabolic dysregulation, which cause the activation of hepatic stellate cells and excessive accumulation of extracellular matrix proteins. Without effective treatments, liver fibrosis can lead to cirrhosis and primary liver cancer. To date, current therapeutic options for liver fibrosis are limited to prevent the initial causing factors for liver inflammation, hepatocyte cell death, and oxidative stress. However, the reverse of liver fibrosis is slowly and frequently impossible for advanced fibrosis or cirrhosis. To avoid the life-threatening stage of liver fibrosis, anti-fibrotic treatments including biological, medicines, dietary change, and behavior prevention are needed, especially for combined therapy. |
| Publish Date |
2023-06-25 14:17 |
| Citation |
Zhang CY, Liu S, Yang M. Treatment of liver fibrosis: Past, current, and future. World J Hepatol 2023; 15(6): 755-774 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i6/755.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i6.755 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
